{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Glioblastoma+Multiforme%28GBM%29&page=2",
    "query": {
      "condition": "Recurrent Glioblastoma Multiforme(GBM)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Glioblastoma+Multiforme%28GBM%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T17:09:38.064Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02626364",
      "title": "Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent/Refractory Glioblastoma"
      ],
      "interventions": [
        {
          "name": "crenolanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arog Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-04",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2020-07-20",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02626364"
    },
    {
      "nct_id": "NCT02194452",
      "title": "Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acoustic Schwannoma",
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Meningioma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Brain Stem Glioma",
        "Adult Choroid Plexus Tumor",
        "Adult Craniopharyngioma",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoblastoma",
        "Adult Ependymoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Grade I Meningioma",
        "Adult Grade II Meningioma",
        "Adult Medulloblastoma",
        "Adult Meningeal Hemangiopericytoma",
        "Adult Mixed Glioma",
        "Adult Myxopapillary Ependymoma",
        "Adult Oligodendroglioma",
        "Adult Papillary Meningioma",
        "Adult Pilocytic Astrocytoma",
        "Adult Pineal Gland Astrocytoma",
        "Adult Pineoblastoma",
        "Adult Pineocytoma",
        "Adult Subependymal Giant Cell Astrocytoma",
        "Adult Subependymoma",
        "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)",
        "Childhood Choroid Plexus Tumor",
        "Childhood Craniopharyngioma",
        "Childhood Ependymoblastoma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebellar Astrocytoma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebellar Astrocytoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Medulloepithelioma",
        "Childhood Supratentorial Ependymoma",
        "Meningeal Melanocytoma",
        "Newly Diagnosed Childhood Ependymoma",
        "Recurrent Adult Brain Tumor",
        "Recurrent Childhood Anaplastic Astrocytoma",
        "Recurrent Childhood Anaplastic Oligoastrocytoma",
        "Recurrent Childhood Anaplastic Oligodendroglioma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Diffuse Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Fibrillary Astrocytoma",
        "Recurrent Childhood Gemistocytic Astrocytoma",
        "Recurrent Childhood Giant Cell Glioblastoma",
        "Recurrent Childhood Glioblastoma",
        "Recurrent Childhood Gliomatosis Cerebri",
        "Recurrent Childhood Gliosarcoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Oligoastrocytoma",
        "Recurrent Childhood Oligodendroglioma",
        "Recurrent Childhood Pilocytic Astrocytoma",
        "Recurrent Childhood Pilomyxoid Astrocytoma",
        "Recurrent Childhood Pineoblastoma",
        "Recurrent Childhood Pleomorphic Xanthoastrocytoma",
        "Recurrent Childhood Protoplasmic Astrocytoma",
        "Recurrent Childhood Subependymal Giant Cell Astrocytoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma",
        "Recurrent Childhood Visual Pathway Glioma",
        "Untreated Childhood Anaplastic Astrocytoma",
        "Untreated Childhood Anaplastic Oligodendroglioma",
        "Untreated Childhood Brain Stem Glioma",
        "Untreated Childhood Cerebellar Astrocytoma",
        "Untreated Childhood Cerebral Astrocytoma",
        "Untreated Childhood Diffuse Astrocytoma",
        "Untreated Childhood Fibrillary Astrocytoma",
        "Untreated Childhood Gemistocytic Astrocytoma",
        "Untreated Childhood Giant Cell Glioblastoma",
        "Untreated Childhood Glioblastoma",
        "Untreated Childhood Gliomatosis Cerebri",
        "Untreated Childhood Gliosarcoma",
        "Untreated Childhood Medulloblastoma",
        "Untreated Childhood Oligoastrocytoma",
        "Untreated Childhood Oligodendroglioma",
        "Untreated Childhood Pilocytic Astrocytoma",
        "Untreated Childhood Pilomyxoid Astrocytoma",
        "Untreated Childhood Pineoblastoma",
        "Untreated Childhood Pleomorphic Xanthoastrocytoma",
        "Untreated Childhood Protoplasmic Astrocytoma",
        "Untreated Childhood Subependymal Giant Cell Astrocytoma",
        "Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Untreated Childhood Visual Pathway and Hypothalamic Glioma",
        "Untreated Childhood Visual Pathway Glioma"
      ],
      "interventions": [
        {
          "name": "gallium Ga 68-edotreotide",
          "type": "RADIATION"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Sue O'Dorisio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "6 Months to 29 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-09",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02194452"
    },
    {
      "nct_id": "NCT07553520",
      "title": "Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Recurrent Glioma"
      ],
      "interventions": [
        {
          "name": "Normal diet",
          "type": "OTHER"
        },
        {
          "name": "Cysteine/methionine deprivation (CMD) diet for 2 days",
          "type": "OTHER"
        },
        {
          "name": "Cysteine/methionine deprivation (CMD) diet for 4 days",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-05",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07553520"
    },
    {
      "nct_id": "NCT00049296",
      "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2002-07",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049296"
    },
    {
      "nct_id": "NCT00501891",
      "title": "Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Metronomic Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-07",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00501891"
    },
    {
      "nct_id": "NCT01967810",
      "title": "ANG1005 in Patients With Recurrent High-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma",
        "Glioblastoma",
        "Brain Tumor, Recurrent"
      ],
      "interventions": [
        {
          "name": "ANG1005",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angiochem Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2013-10",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01967810"
    },
    {
      "nct_id": "NCT00045110",
      "title": "Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Grade I Meningioma",
        "Adult Grade II Meningioma",
        "Adult Grade III Meningioma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2002-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045110"
    },
    {
      "nct_id": "NCT00024557",
      "title": "Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma",
        "Mixed Oligoastrocytoma",
        "Malignant Astrocytoma"
      ],
      "interventions": [
        {
          "name": "IL13-PE38QQR",
          "type": "DRUG"
        },
        {
          "name": "targeted fusion protein therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2001-06",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2011-06-06",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • New Haven, Connecticut • New York, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024557"
    },
    {
      "nct_id": "NCT02933736",
      "title": "Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Meningioma"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nader Sanai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2016-10-17",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02933736"
    },
    {
      "nct_id": "NCT07268053",
      "title": "A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma (GBM)",
        "Brain Metastasases"
      ],
      "interventions": [
        {
          "name": "Risvutatug rezetecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nader Sanai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2026-02-11",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-07-23T17:09:38.064Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07268053"
    }
  ]
}